Sanofi stopped its phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring committee judged the study unlikely to provide sufficient efficacy, even without safety concerns. The decision adds to a run of R&D setbacks as Sanofi evaluates whether to continue additional phase 3 work. Separately, Camurus again received a complete response letter from the FDA for Oclaiz (CAM-2029), its subcutaneous extended-release injection for acromegaly. This repeat rejection shifts the U.S. timeline for the branded launch while the drug remains authorized in the EU and U.K., where it received marketing authorization in 2025.